Adjuvants play a determinant role in
cancer vaccination by optimally activating APCs and shaping the T cell response. Bacterial-derived
lipid A is one of the most potent immune-stimulators known, and is recognized via
Toll-like receptor 4 (TLR4). In this study, we explore the use of the synthetic, non-toxic,
lipid A analog
CRX-527 as an adjuvant for
peptide cancer vaccines. This well-defined adjuvant was covalently conjugated to antigenic
peptides as a strategy to improve
vaccine efficacy. We show that coupling of this TLR4 agonist to
peptide antigens improves
vaccine uptake by dendritic cells (DCs), maturation of DCs and T cell activation in vitro, and stimulates DC migration and functional T cell priming in vivo. This translates into enhanced
tumor protection upon prophylactic and therapeutic vaccination via
intradermal injection against B16-OVA
melanoma and HPV-related TC1
tumors. These results highlight the potential of
CRX-527 as an adjuvant for molecularly defined
cancer vaccines, and support the design of adjuvant-
peptide conjugates as a strategy to optimize
vaccine formulation.